A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
OBJECTIVE
To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS).


METHODS
Infants with RDS were randomized to receive beractant or poractant. The primary outcome measure was fraction of inspired oxygen (FiO2) requirement in the first 48 h after surfactant therapy.


RESULTS
58 infants completed the study. The mean gestational ages for the poractant and beractant groups were 29.6+/-3.6 and 29.3+/-2.9 wk, with average birthweights of 1394+/-699 and 1408+/-534 g, respectively. In the first 48 h, infants who received poractant had a lower FiO2 requirement compared to those who received beractant (p=0.018). The prevalence of patent ductus arteriosus (PDA) was lower in the group of infants that received poractant (17%) compared to the group that received beractant (45%) (p=0.02).


CONCLUSIONS
Infants with RDS treated with poractant had a lower FiO2 requirement during the first 48 h compared to infants who received beractant. Infants who received poractant also had fewer PDAs than infants who received beractant. The difference in FiO2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups.
Malloy
Colleen Ann
CA
Division of Neonatology, Department of Pediatrics, Ronald McDonald Children's Hospital at Loyola University Medical Center, Maywood, IL 60153, USA. c-malloy@northwestern.edu
Nicoski
Pamela
P
Muraskas
Jonathan K
JK
D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010743:Phospholipids / Q000627:therapeutic use*; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D016896:Treatment Outcome
D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa; C072197:beractant